Drug Profile
Albenatide
Alternative Names: CJC-1134; CJC-1134-PC; PC-DAC™:Exendin-4Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator ConjuChem Biotechnologies
- Developer ConjuChem; Kaijiejian Biopharmaceutical
- Class Albumins; Antihyperglycaemics; Peptides; Small molecules; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 03 Apr 2019 Preclinical data for Solid tumours presented at the Annual Meeting of the American Association of Cancer Research (AACR-2019)
- 01 Jan 2019 Preclinical trials in Solid tumours in China (Parenteral)